美国第三方体外受精的应用情况
该回顾性分析纳入2004—2013年美国1,349,874个体外受精周期,其中第三方体外受精占16.1%的周期、20.4%的活产和20.9%的活产婴儿。第三方体外受精周期活产率为39.7%,高于自体体外受精周期的29.6%;在40岁以上女性中,第三方体外受精占42.2%的周期和75.3%的活产婴儿。
要点
- 第三方体外受精占全部体外受精周期的16.1%、活产的20.4%和活产婴儿的20.9%。
- 第三方体外受精周期活产率39.7%,自体体外受精周期为29.6%。
- 40岁以上女性中,第三方体外受精占42.2%的周期和75.3%的活产婴儿。
核心结论
- 过去十年第三方体外受精的使用和有效性均增加,现已占体外受精出生队列的20%以上;在40岁以上女性中已成为主导治疗。
研究设计与样本
- 回顾性分析美国2004—2013年1,349,874个体外受精周期,来自辅助生殖技术诊所结局报告系统(Society for Assisted Reproductive Technologies Clinic Outcome Reporting System)的生育中心自报数据,共421,525例活产和549,367例活产婴儿。
主要发现
- 第三方体外受精占217,030个周期(16.1%)、86,063例活产(20.4%)和115,024例活产婴儿(20.9%)。
- 第三方体外受精周期活产率为39.7%,自体体外受精周期为29.6%。
- 第三方体外受精的使用随母亲年龄增加,在40岁以上女性中占42.2%的周期和75.3%的活产婴儿。
- 卵子捐赠是最常见的第三方体外受精技术,其次是精子捐赠。
- 研究期间,自体体外受精和第三方体外受精的年周期量和活产率均逐渐增加(所有P<.0001);使用多种第三方体外受精方式时活产率最高,其次是卵子捐赠。
关键数值与推荐
- 第三方体外受精周期活产率39.7%,自体体外受精周期活产率29.6%。
- 40岁以上女性中,第三方体外受精占42.2%的体外受精周期和75.3%的活产婴儿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of in vitro fertilization that includes third-party in vitro fertilization is increasing. However, the relative contribution of third-party in vitro fertilization that includes the use of donor oocytes, sperm, or embryo and a gestational carrier to the birth cohort after in vitro fertilization is unknown. OBJECTIVE: The purpose of this study was to examine the contribution of third-party in vitro fertilization to the in vitro fertilization birth cohort over the past decade. STUDY DESIGN: This retrospective analysis investigated 1,349,874 in vitro fertilization cycles that resulted in 421,525 live births and 549,367 liveborn infants in the United States from 2004-2013. Cycles were self-reported by fertility centers to a national registry: Society for Assisted Reproductive Technologies Clinic Outcome Reporting System. RESULTS: Third-party in vitro fertilization accounted for 217,030 (16.1%) of all in vitro fertilization cycles, 86,063 (20.4%) of all live births, and 115,024 (20.9%) of all liveborn infants. Overall, 39.7% of third-party in vitro fertilization cycles resulted in a live birth, compared with 29.6% of autologous in vitro fertilization cycles. Use of third-party in vitro fertilization increased with maternal age and accounted for 42.2% of all in vitro fertilization cycles and 75.3% of all liveborn infants among women >40 years old. Oocyte donation was the most common third-party in vitro fertilization technique, followed by sperm donation. Over the study period, annual cycle volume and live birth rates gradually increased for both autologous in vitro fertilization and third-party in vitro fertilization (P<.0001 for all). Live birth rates were the highest when multiple third-party in vitro fertilization modalities were used, followed by oocyte donation. CONCLUSION: Third-party in vitro fertilization use and efficacy have increased over the past decade, now comprising >20% of the total in vitro fertilization birth cohort. In women who are >40 years old, third-party in vitro fertilization has become the dominant treatment.
引用
- Kushnir VA, Darmon SK, Shapiro AJ, et al. Utilization of third-party in vitro fertilization in the United States. Am J Obstet Gynecol. 2016. PMID: 27856185. doi:10.1016/j.ajog.2016.11.1022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。